

PLANT RESEARCH BREIFING PAPERS - Dr. Bob Buchanan Explains How His Research Using Plant Biotechnology Is Removing Allergens from Existing Foods
Statement of
Bob
B. Buchanan, Ph.D.
Professor
University of California
Berkeley, California
Senate Committee on Agriculture, Nutrition,
and Forestry/center>
October 6, 1999
Thank
you Mr. Chairman for the invitation to appear
today before the Committee. My name is Bob B.
Buchanan and I am a Professor and former Chair
of the Department of Plant and Microbial Biology
at the University of California at Berkeley.
I am especially pleased to appear before this
Committee because I have been a part of agriculture
all my life. I grew up on a family farm in Virginia,
that my sister and I continue to own, and I
have spent my entire professional career at
a land grant university focusing on plant biochemistry,
plant molecular biology and now plant biotechnology.
I have also given professional service to agriculture
in several capacities.
Today
we are at the dawn of a new age in promoting
and enhancing human health through the use of
genetic engineering technology to improve the
food choices available to the consumer. Beneficiaries
of this new technology will be the consumer,
the farmer and those entrepreneurial companies
currently spending precious risk capital to
bring these important opportunities and benefits
to a commercial reality. The consumer will receive
benefits not only from improved foods, but also
in the areas of human and veterinary medicine.
My
particular area of interest includes development
of genetically engineered cereals with improved
qualities such as reduced allergenicity and
increased processing qualities. One vision is
to generate hypoallergenic cereals such as wheat
for inclusion into cereal based food products.
I
would like to summarize our work, giving a snapshot
to the distinguished Senators of how sustained
basic scientific research may result in practical
solutions to significant heretofore-unresolved
problems.
The
current work to reduce allergens and improve
cereals was not the target of my initial research.
Rather, the story begins with research initiated
in Berkeley more than thirty years ago. Our
early efforts led to the discovery that thioredoxin,
a small protein earlier found in bacteria by
others, functions in regulating photosynthesis.
In fulfilling this function, thioredoxin, in
effect, acts as an "eye," allowing chloroplasts,
the site of photosynthesis, to distinguish light
from dark. The chloroplast thioredoxin system
functions by breaking critical intrachain disulfide
bonds on key enzymes thereby altering their
activity in the light. In this way, the plant
is able to maximize the energy obtained from
the sun.
As
our photosynthesis findings began to be accepted
and incorporated into mainstream textbooks,
I considered my contribution to the field to
be complete and turned my attention to the function
of a different type of thioredoxin we had found
to occur outside chloroplasts--i.e., thioredoxin
h. This effort led ten years ago to the discovery
that thioredoxin h acts as a "wake up call"
in the germination of cereals. In wheat and
other cereals examined, thioredoxin functions
in the first few days of germination to enhance
the mobilization of carbon and nitrogen and
thereby nourish the new seedling. Thioredoxin
acts by facilitating the degradation of protein
and starch reserves. The work reported today
covered thirty six years of my professional
time, and more than two centuries of the collective
time, energy and effort of graduate and postdoctoral
students and technicians.
Research
initiated soon after our entry into the cereal
field prompted the realization that thioredoxin
could be applied as a new tool in technology
and medicine. Much of this early effort was
accomplished jointly with Dr. Karoly Kobrehel,
a cereal technologist at the Institut National
de la Recherche Agronomique, Montpellier, France,
who spent a sabbatical year in our laboratory.
In
vitro studies. Research done at the biochemical
or protein level has identified a role for thioredoxin
in far-reaching applications. The results have
opened the door to the application of thioredoxin
in fields ranging from nutrition and food technology
to medicine. In vitro experiments have demonstrated
that thioredoxin
Alleviates food and pollen allergies,
Enhances the digestibility and nutritional quality
of foods,
Improves the baking quality of poor quality
flour, and
Disarms neurotoxins of snakes, scorpions and
bees.
In
addition, we have developed an animal model
to provide the first:
Allergy test for genetically modified foods.
A
unique capability of our effort involves the
use of an animal model to determine whether
cereals with altered thioredoxin levels have
a reduced allergenicity. This is a sophisticated
area of immunology. Our research with allergies
stems from a collaboration with Dr. Oscar L.
Frick, an allergy specialist from the School
of Medicine, University of California, San Francisco.
Good fortune led to me to meet Dr. Frick seven
years ago and start work that has led to the
discovery that treatment of major allergenic
foods such as wheat, milk and soy with thioredoxin
decreases their allergenicity. Dr. Frick has
spent many years studying food allergy responses
in humans. Most of our work has been done with
an animal model that seems ideal to study human
allergies. Clinical work elsewhere has extended
certain of our findings to humans. The application
of thioredoxin to liquid foods--milk and soymilk--will
soon be turned over to a company to proceed
with the further testing to develop hypoallergenic,
hyperdigestible infant formulas. Work to date
indicates that we can adapt our animal model
to test genetically modified foods for new allergens.
Transgenic
cereals. The initial work on thioredoxin h could
not be extended to transgenic cereals until
appropriate molecular genetic technology was
developed. This is where my story intersects
with another University of California researcher.
Dr. Peggy Lemaux is a pioneer in developing
technologies and methodologies for the transformation
of cereals that can be practically reproduced
and exploited in academic and industrial laboratories
throughout the world. Historically, cereals
were very difficult to transform and it was
through the sustained efforts of individuals
such as Dr. Lemaux that success was achieved.
The contribution opened the door for improvement
of grains through addition of thioredoxin h
by using genetic engineering technologies. In
collaboration with her laboratory we have generated
transgenic barley lines with thioredoxin overexpressed
exclusively in the grain. Ongoing studies have
shown that transgenic grain have beneficial
properties that we are just beginning to explore.
We recently found that thioredoxin can also
be overexpressed in wheat.
The
availability of the transgenic barley and wheat
grain has opened a new door both to study the
biological role of thioredoxin and to apply
thioredoxin cost effectively in technology and
medicine. To this latter end we are presently
formulating projects with several companies
to do the research needed to facilitate technology
and product movement from our laboratories to
the industrial development laboratory and eventually
to the marketplace at a rapid pace.
Our
current transgenic cereal research program ranges
from studies on fundamental seed biology to
technology development and application. We wish
to learn more about the function of thioredoxin
by use of transgenic plants and at the same
time improve the nutritional or functional properties
of major foods. For example, in cooperation
with Dr. Frick, we seek to gain an understanding
as to how thioredoxin from our laboratory, when
engineered into cereals by Dr. Lemaux's group,
could benefit humans. In addition to barley
and wheat, our agenda includes rice, corn, sorghum,
soybean and peanuts. The practical question
with respect to transgenic plants is quite simple:
can the value-added properties observed with
thioredoxin in vitro be conferred to transgenic
seeds by the overexpressed thioredoxin h gene?
If the answer is "yes," thioredoxin could have
impact across the food industry.
Relevance
to medicine. Another focus of our work relates
to medicine. Recent work with pollen indicates
that we may be able to improve the effectiveness
and safety of the desensitization procedure
currently used to protect against allergies.
We plan to pursue this possibility by providing
disarmed allergens to our animal model by injection.
Human trials would follow. In a joint project
with Dr. Susanne Teuber, an allergy specialist
from the School of Medicine, University of California,
Davis, we are also working on peanuts and tree
nuts--foods that cause life-threatening allergies.
This work is just getting under way but we are
optimistic that we may be able to help understand
why allergies to these foods are lifelong. Experiments
to mitigate the allergic response to nuts are
currently being planned.
Benefits.
I mentioned earlier that this work has the potential
to benefit the consumer, the farmer and entrepreneurial
companies. Let me explain.
Consumers
will benefit from these improved foods.
The
American Academy of Allergy and Immunology Committee
on Adverse Reactions to Food has defined food
hypersensitivity allergy as "an immunological
reaction resulting from the ingestion of a food
or a food additive" whereas food intolerance
is "a general term describing an abnormal physiologic
response to an ingested food or food additive;
this reaction is not proven to be immunologic."
Of
all adverse reactions to food and food additives,
greater than 20% are due to true "allergy" or
"hypersensitivity," in which a definite immunopathologic
process can be documented and a cause-and-effect
relationship can be proven.
When
an allergic person eats offending food, the
body overreacts and releases histamine and other
biochemicals, resulting in allergy symptoms
which can include itchy eyes; rash or hives;
runny nose; swelling of the lips, tongue, and
face; itching or tightness of the throat; abdominal
pain; nausea; diarrhea; and shortness of breath.
In some cases, the smell or inhalation of aromas
from food containing allergens is sufficient
to cause a reaction. Some people have severe
or anaphylactic reactions. In addition to the
previously-identified symptoms, these reactions
can include a dangerous drop in blood pressure
and even unconsciousness. These reactions can
be fatal without immediate medication and medical
attention leading to about 2,500 emergency room
visits and 135 deaths per year in the United
States. In the United States, eight foods account
for 90 percent of all allergenic reactions:
milk, eggs, wheat, soy, peanuts, tree nuts,
fish and shell-fish. These responses may occur
within minutes or within a few hours after eating
the offending food.
Conservatively,
in the United States, food allergies develop
in 1% and possibly as high as 3% of older children
and adults and about 5 to 8% of infants and
toddlers. In countries such as Japan, the incidence
is much higher and is increasing. A significant
percentage of these allergy problems results
from allergens contained in certain cereals
consumed as food. Further, airborne allergens
from wheat in bakeries and confectioneries cause
one of the most common forms of occupational
asthma, namely bakers' asthma. Food allergies
are also seen in about 10% of pet dogs and cats.
There
is no cure for food allergies. Once a diagnosis
is made, complete avoidance of that food is
the only way to avoid symptoms. Patients must
learn the scientific and technical names of
foods and read ingredient labels carefully.
Labels must be read before making a purchasing
decision every time the patient goes to the
store, because ingredients may change without
warning. For example, individuals with wheat
allergy must restrict their use of wheat-containing
foods--a growing problem as wheat gluten is
increasingly used by the food industry. In our
culture, it is not uncommon for us to eat wheat
at every meal, thus adhering to a wheat free
diet may be difficult. There is a growing international
effort to require that allergenic foods carry
hypersensitivity labeling and products with
cereals containing allergenic gluten (wheat,
barley, rye and oats) will be affected.
It
is our goal that someday food products containing
cereals will be formulated with hypoallergenic
grain so that persons with cereal allergies
can eat a wide range of food products without
fear of significant health related injuries
or concerns.
Farmers
will benefit from these engineered products.
In
the United States the sad reality for many farmers
is that the harvest price for cereals is close
to the total economic cost of production. As
a result, American farmers barely earn a living.
When transgenic cereals can be used in high
value food and animal feed owing to the presence
of output traits, the premium paid for the cultivation,
harvest and processing of the proprietary grains
will give the farmer additional income. The
increased value of the new products will make
the transgenic cereals grown more than a commodity.
Once it is shown that these grains can be used
in high value formulated foods, the grain itself
(the key ingredient) commands a premium in production.
The successful completion of this project will
stand as a beacon of realizable financial advantages
for cereal farmers trapped with low commodity
prices (often below costs) and the ebbing of
critical subsidies.
Entrepreneurial
companies and hence the American economy will
also benefit.
Several
entrepreneurial companies are currently spending
precious risk capital to advance this project
to a commercial reality. These companies are
taking significant risks, but if the project
is successful, they will benefit, and in so
doing, will benefit the American economy.
Finally,
let me add that diverse elements of society
will benefit if this work is successful. The
research to be accomplished during the next
several years will potentially lead to products
that will improve the quality of life across
geographical and political boundaries. First,
economically advanced countries will benefit
through the introduction of improved foods and
drinks and medical procedures to be developed
through commercial channels. Once we take each
to a suitable stage and learn what basic biology
we can during this journey, the technologies
and products will be passed on to companies
for further testing and commercial development.
The marketplace will be the next destination.
A
second contribution of new and improved food
products is for developing countries. Here we
can contribute by increasing the digestibility
and thereby improving the nutritional value
of crops indigenous to tropical and subtropical
areas--e.g., rice, one of the world's major
crops, and sorghum, a cereal especially important
to Africa and other parts of the developing
world where corn fails to grow. Humans or domesticated
animals do not digest a significant fraction
of the protein of sorghum and certain rice varieties.
Transforming rice and sorghum grain with the
thioredoxin h gene, therefore, opens the door
to increasing the dietary protein available
from both foods. At the same time, it could
change the world market for sorghum.
Another
area in which thioredoxin may find application
for developing countries relates to new food
products. We have obtained evidence that thioredoxin
and related natural components (NADP-thioredoxin
reductase, NADPH) added in vitro, make it possible
to generate new dough-like products from sorghum,
corn and rice flours. Grains such as these are
otherwise nonglutenous--i.e., incapable of dough
formation. We are optimistic that overexpressed
thioredoxin h may render these grains capable
of forming new dough-based products. We plan
to extend these studies during the next two
years. I am in contact with the Food and Agriculture
Organization of the United Nations and we also
plan to select a foundation to assist with the
project.
Concluding
remarks. The research we are currently doing
stems from studies initiated at the start of
my career at Berkeley more than thirty years
ago. Discoveries made on the role of thioredoxin
in photosynthesis led to research that has given
new insight into seed germination. Experiments
built on these results suggest that thioredoxin
could find broad application in technology and
medicine and improve the quality of life worldwide.
In
closing, I wish to commend the Committee for
giving scientists an opportunity to help clarify
misunderstandings surrounding genetically modified
foods and to show that there is progress toward
products that will benefit all of humanity.
I also wish to acknowledge support from the
NSF, USDA and NIH that made possible our fundamental
research and to the USDA NRI which enabled Dr.
Lemaux and me to start our present project on
seed biotechnology. Finally, I want to mention
that the lines separating these agencies are
disappearing. The time is ripe for federal agencies
to support cooperative programs that cut across
the traditional boundaries of basic biology,
agriculture, nutrition and medicine. Much of
the nation's future rests on knowledge, technologies
and products that will come from an integration
of these diverse fields.